Regulatory approval

Published by the Health Service Executive. Approved

The Republic of Ireland's Health Service Executive (HSE) has approved vemurafenib for reimbursement as a monotherapy treatment option for the treatment of adult patients with unresectable or metastatic melanoma whose tumors are BRAF V600 positive.

This is written in the approval document as:

Treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.

Reimbursement

CDS

Citation

Vemurafenib Monotherapy, 2025, version number 6, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6723/102_v6_Vemurafenib_Monotherapy.pdf

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies
HSE (1)	BRAF p.V600E	Melanoma	Vemurafenib
HSE (1)	BRAF p.V600K	Melanoma	Vemurafenib

Contributions

Date	Contributor	Description
2024-01-16	Van Allen lab	Adding HSE approvals for reimbursement to database
2013-03-07	Health Service Executive	Indication approved for reimbursement.